Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
Nat Rev Immunol
; 22(2): 85-96, 2022 02.
Article
in English
| MEDLINE | ID: covidwho-2133458
ABSTRACT
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds on scientific developments in tumour immunology, genetic engineering and cell manufacturing, best illustrated by the curative potential of chimeric antigen receptor (CAR) T cell therapy targeting CD19-expressing malignancies. However, the clinical benefit observed in many patients may come at a cost. In up to one-third of patients, significant toxicities occur that are directly associated with the induction of powerful immune effector responses. The most frequently observed immune-mediated toxicities are cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This Review discusses our current understanding of their pathophysiology and clinical features, as well as the development of novel therapeutics for their prevention and/or management.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Neurotoxicity Syndromes
/
Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Nat Rev Immunol
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
S41577-021-00547-6
Similar
MEDLINE
...
LILACS
LIS